Farmacoriflessioni
Il reflusso gastroesofageo: intendiamoci sulle parole
Gastroesophageal reflux: let’s be clear on the meaning of the words
Doriana Lacorte1, patrizia Alvisi2, Andrea lambertini2, Alessandro Ventura3, federico Marchetti4
1Scuola di Specializzazione di Pediatria, Azienda Ospedaliero-Universitaria S. Anna, Ferrara
2UOC di Pediatria, Ospedale Maggiore, Bologna
3IRCCS Materno-Infantile “Burlo Garofolo”, Università di Trieste
4UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna
Febbraio 2016 - pagg. 98 -102
Abstract
Although gastroesophageal reflux in infants is physiological and resolves spontaneously,
pharmacological treatment in the paediatric population is continuously increasing despite
the dissemination of recent guidelines that focus on a non-interventionist approach
and emphasise the importance of ex-planation and reassurance. Acid reducing medications,
widely used to alleviate manifestation commonly diagnosed as gastroesophageal
reflux disease, are ineffective for symptom relief and carry significant risk of harm. The
factors that lead to overtreatment are not well understood. Probably, the use of the definition
“gastroesophageal reflux” itself increases the perception of illness severity and influences
parents’ interest in medicating their infants.
Parole chiave
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. National Institute of Healt and Care Excellence
(NICE). Clinical Knowledge Summaries
on Gastroesofagea reflux disease in children.
http://cks.nice.org.uk/gord-in-children
(ultimo accesso 7 dicembre 2015).
2. Borraccino A, Ravaglia A. Prescrizione di
antiacidi, anti-H2 e IPP nei primi tre anni di
vita nella Regione Piemonte. Un’analisi di
comportamenti “off-label”. Medico e Bambino
2014;33(10);647-51.
3. Ventura A. Il pediatra e il reflusso gastroesofageo.
Medico e Bambino 2009;28(4):211-2.
4. Hassall E. Over-prescription of acid-suppressing
medications in infants: how it came
about, why it’s wrong, and what to do about
it. J Pediatr 2012;160(2):193-8.
5. Puntis JW. Gastro-esophageal reflux in
young babies: who should be treated? Arch
Dis Child 2015;100:989-93.
6. Vandenplas JR, Rudolph CD, Di Lorenzo
C, et al. North American Society for Pediatric
Gastroenterology, Hepatology and Nutrition;
European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition. Pediatric gastro-
esophageal reflux disease clinical practice
guidelines: joint recommendations of the
North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition
(NASPGHAN) and the European Society for
Pediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN). J Pediatr Gastroenterol
Nutr 2009;49:498-547.
7. Cavallo R. Linee guida per la diagnosi e la
terapia del reflusso gastroesofageo. Raccomandazioni
congiunte della Società Europea
(ESPGHAN) e Nord Americana (NASPGHAN)
di Gastroenterologia, Epatologia e
Nutrizione Pediatrica. Medico e Bambino
2012;31(2):89-98.
8. Quitadamo P, Papadopoulou A, Wenzl T,
et al. European pediatricians’ approach to
children with GER symptoms: survey of the
implementation of 2009 NASPGHAN-ESPGHAN
guidelines. J Pediatr Gastroenterol
Nutr 2014;58:505-9.
9. Marchetti F. L’eccesso di diagnosi e trattamento
per il presunto reflusso gastroesofageo.
Come è nato, perché è sbagliato, e cosa
possiamo fare. Medico e Bambino 2012;31
(2):99-101.
10. Murgia V. Efficacia degli inibitori di pompa
protonica nei bambini con reflusso gastroesofageo:
una revisione sistematica. Medico e
Bambino Pagine elettroniche 2013; 16(6).
11. Thaler MM. Non compliance with NASPGHAN-
ESPGHAN practice guidelines for
GER in Europe: is there a point? J Pediatr Gastroenterol
Nutr 2014;58:396-7.
12. Diaz DM, Winter HS, Colletti RB, et al.
Knowledge, attitudes, and practice styles of
North American pediatricians regarding gastroesophageal
reflux disease. J Pediatr Gastroenterol
Nutr 2007;45(1):56-64.
13. Putnam PE. Stop the PPI express: they
don’t keep babies quiet! J Pediatr 2009;154
(4):475-6.
14. Karacetin G, Demir T, Erkan T, et al. Maternal
psychopathology and psychomotor development
of children with GERD. J Pediatr
Gastroenterol Nutr 2011;53(4):380-5.
15. Taddio A, Bersanini C, Basile L, Fontana
M, Ventura A. Gastroesophageal reflux disease
at any cost: a dangerous paediatric attitude.
Acta Paediatr 2011;100(10):e178-80.
16. Grassi M, Cecinati V, De Leonardis F, et
al. Un reflusso gastroesofageo molto maligno.
Medico e Bambino Pagine elettroniche
2010;13(8).
17. Nelson SP, Chen EH, Syniar GM, et al.
Prevalence of symtoms of gastroesophageal
reflux during infancy. Arch Pediatr Adolesc
Med 1997;151:596-72.
18. Nelson SP, Chen EH, Syniar GM, et al. One
year follow up of symptoms of gastroesophageal
reflux in infancy. Pediatrics 1998; 102:e67.
19. Marchetti F. Indicazioni per l’utilizzo razionale
dei farmaci antiacidi (anti-H2 e IPP).
Medico e Bambino 2009;28(4):250-4.
20. Tornese G, Maschio M, Marchetti F,
Ventura A. To GERD or not to GERD, this is
the question. J Pediatr 2009;155(4):601.
21. Douglas P, Hill P. Managing infants who
cry excessively in the first few months of life.
BMJ 2011;343:d7772.
22. Orestein SR, Hassal E, Furmaga-Jablonska
W, et al. Multicentre, double blind randomized
placebo-controlled trial assessing
the efficacy of proton pump inhibitor lansoprazole
in infants with symptoms of gastroesophageal
reflux disease. J Pediatr 2009;154:
514-20.
23. Bialek-Gieruszczaak D, Skorka A. No effect
of proton pump inhibitors on crying and
irritability in infants: systematic review of
randomized controlled trials. J Pediatr 2015;
166(3):767-70.
24. Fornaro M, Dal Bon E, Bissolo F, Bodini
A, Valletta E. Indicazioni alla pH-metria esofagea.
Medico e Bambino 2009;28(4):243-7.
25. Vigo A, Noce S, Ravaglia A. Per una corretta
gestione del bambino con ALTE. Medico
e Bambino 2015;34(5):292-7.
26. Scherer LD, Zikmund-Fisher BJ, Fagerlin
A, et al. Influence of “GERD” label on parents’
decision to medicate infants. Pediatrics
2013;131(5):839-45.
Corrispondenza: federico.marchetti@ausl.ra.it